Mutation burden is typically assessed through next-generation sequencing (NGS) of tumor samples. The process involves extracting DNA from the cancer tissue, sequencing it, and identifying mutations. The results are then normalized to the size of the genome to provide a mutations per megabase (mut/Mb) score. Whole-exome sequencing (WES) and targeted gene panels are commonly used methods for this purpose.
